|
Real Time
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 0,5140 EUR | -1,91% |
|
-16,01% | -66,54% |
| 13/07 | AB Science staakt drie klinische studies met masitinib | MT |
| 10/07 | AB Science rationaliseert portefeuille en focust op twee moleculen |  |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Evolutie 1 maand | Evolutie 3 maanden | Var. 1 jan | Varia. 1j. | Varia. 3j. | Varia. 5j. | Varia. 10j. | Kap.($) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -1,91% | -16,01% | -40,92% | -55,69% | -66,54% | -60,52% | -87,60% | -96,58% | -96,32% | 47,67 mln. | |
| +2,36% | +2,23% | +9,10% | +13,84% | +23,96% | +55,37% | +18,20% | +68,27% | +121,83% | 322 mld. | |
| +1,17% | +3,08% | +0,29% | +25,56% | +14,60% | +23,95% | -10,82% | -18,24% | +44,92% | 68,84 mld. | |
| +3,88% | +4,26% | +16,12% | +21,40% | +20,12% | +38,05% | +88,48% | +88,48% | +774,89% | 9,59 mld. | |
| +0,93% | -1,38% | +2,49% | +11,33% | +3,60% | +1,71% | -4,10% | -29,91% | +35,86% | 8,29 mld. | |
| +3,78% | +0,38% | -3,04% | -22,62% | -36,04% | -21,63% | -6,67% | -34,67% | - | 4,23 mld. | |
| +0,07% | -6,67% | +4,11% | +21,74% | +30,11% | -3,14% | +22,21% | -36,69% | - | 3,77 mld. | |
| +1,71% | +0,85% | +2,29% | -24,60% | -36,48% | -42,97% | +11,90% | +34,18% | +72,93% | 3,61 mld. | |
| +0,53% | -2,12% | +6,09% | -6,35% | -5,05% | +43,13% | +54,17% | +73,05% | +124,39% | 2,74 mld. | |
| -0,30% | -5,84% | +6,78% | -14,33% | -16,87% | +3,61% | -10,21% | +49,86% | - | 2,13 mld. | |
| +0,61% | -2,44% | +17,56% | -1,12% | +2,43% | -14,56% | +37,29% | -28,02% | - | 1,96 mld. | |
| -0,80% | -5,85% | +3,58% | -11,05% | -13,96% | -21,85% | -18,33% | -9,48% | -43,53% | 1,72 mld. | |
| -.--% | -.--% | - | - | - | - | - | - | - | 1,64 mld. | |
| -0,98% | -10,21% | -3,66% | -24,53% | -15,96% | -35,77% | -31,28% | - | - | 1,19 mld. | |
| +1,28% | +18,69% | +31,80% | +92,16% | +161,03% | +188,69% | +1.386,20% | +689,62% | - | 1,21 mld. | |
| +3,31% | -15,75% | +10,11% | +11,80% | +17,62% | -6,56% | +98,23% | +14,08% | - | 1,17 mld. | |
| +0,24% | +1,56% | +5,75% | -7,34% | -9,03% | 0,00% | +40,07% | +86,34% | +75,96% | 1,07 mld. | |
| +2,92% | -0,19% | -8,17% | -41,98% | -41,40% | +33,84% | +26,32% | +15,20% | +425,37% | 1,1 mld. | |
| -0,14% | -7,12% | -1,98% | -19,01% | -23,86% | -37,02% | -75,68% | -84,12% | - | 877 mln. | |
| -2,89% | -0,84% | -1,26% | -16,07% | -15,47% | -46,47% | -13,92% | -48,01% | -66,38% | 871 mln. | |
| Gemiddelde | +0,69% | +0,71% | +3,00% | -2,47% | -0,38% | +5,15% | +80,23% | +40,74% | +133,63% | 21,92 mld. | |
| Gewogen gemiddelde per kap. | +0,58% | +2,58% | +7,44% | +14,55% | +20,18% | +45,37% | +18,19% | +51,12% | +121,62% |
Kies jouw editie
Alle financiële informatie op nationaal niveau
